Written By :- Ali Jan
Pakistan’s pharmaceutical industry is undergoing a major transformation driven by regulatory reforms, policy coordination, and investment facilitation under the Special Investment Facilitation Council (SIFC). Long constrained by policy uncertainty, restrictive pricing mechanisms, and limited integration with international markets, the sector is increasingly emerging as a competitive, investment-friendly, and export-oriented industry capable of contributing significantly to healthcare and economic growth.
The pharmaceutical sector occupies a vital position in Pakistan’s economy and public health system, supplying medicines to more than 240 million people while supporting a substantial domestic manufacturing base. Despite its importance, the industry has faced persistent challenges, including rising production costs, currency depreciation, and heavy dependence on imported Active Pharmaceutical Ingredients (APIs). Rigid price controls and frequent regulatory changes further complicated long-term planning and discouraged investment.
These difficulties had serious consequences. Several multinational pharmaceutical companies reduced operations, reviewed investment plans, or exited the market due to concerns over commercial sustainability and regulatory uncertainty. Domestic manufacturers also faced operational pressures that occasionally led to medicine shortages and supply disruptions. Although Pakistan possesses considerable manufacturing capacity, pharmaceutical exports remained below their potential.
To address these challenges, SIFC brought together the Ministry of National Health Services, the Drug Regulatory Authority of Pakistan (DRAP), and industry stakeholders to develop coordinated solutions. This collaborative approach has helped create a more stable policy environment while promoting reforms that support both healthcare outcomes and industrial growth.
Among the most significant reforms has been the revision of medicine pricing policies. Following extensive consultations, a new pricing framework deregulated non-essential medicines while maintaining protections for essential and life-saving drugs. This balanced approach has improved commercial viability for manufacturers while safeguarding public access to critical treatments.
The reform agenda has also expanded into other important areas. The National Essential Medicines List (NEML) has strengthened the prioritization and availability of medicines across the healthcare system. The National Vaccine Policy is expected to encourage domestic vaccine production, reduce import dependence, and create new export opportunities. Additional initiatives under development include a National API Policy, a National Thalassemia Policy, and comprehensive Stem Cell Therapy Guidelines aimed at modernizing Pakistan’s healthcare and pharmaceutical framework.
Industry response to these reforms has been positive. Enhanced pricing flexibility has improved production viability, strengthened medicine availability, and supported continuity of supply. Regulatory measures introduced to address hardship cases in 2024 further eased supply pressures and contributed to market stability.
A key focus of ongoing reforms is aligning Pakistan’s pharmaceutical sector with international regulatory standards. Compliance with the Pharmaceutical Inspection Co-operation Scheme (PIC/S) is essential for accessing highly regulated global markets. Historically, limited adherence to internationally recognized Good Manufacturing Practices (GMP) restricted export growth, particularly to Europe and other advanced economies.
To improve international competitiveness, efforts are underway to strengthen export support mechanisms and facilitate access to foreign markets. A major achievement has been DRAP’s acquisition of Observer Status in the International Council for Harmonisation (ICH), helping align Pakistan’s regulatory framework with globally accepted standards. Progress toward achieving WHO Global Benchmarking Tool Maturity Level 3 status further demonstrates Pakistan’s commitment to strengthening regulatory effectiveness and international credibility.
SIFC has also accelerated cooperation between regulators and manufacturers to improve inspection systems, strengthen quality assurance mechanisms, and enhance compliance across the industry. Meanwhile, DRAP’s digital transformation initiatives have streamlined regulatory procedures, increased transparency, and reduced administrative delays, creating a stronger foundation for integration into global pharmaceutical supply chains.
Important progress has also been achieved through the National Blood Transfusion Policy, which introduces plasma fractionation capabilities for the first time in Pakistan. Previously, plasma-derived medicinal products used to treat immune deficiencies, bleeding disorders, and other serious conditions were entirely imported. The policy creates opportunities for domestic plasma processing facilities, reducing import dependence while attracting investment in specialized pharmaceutical manufacturing.
These reforms have significantly improved investor confidence by reducing uncertainty surrounding pricing, approvals, and regulatory procedures. Through SIFC’s structured engagement platform, communication between government institutions and private-sector stakeholders has improved considerably, enabling faster problem-solving and greater transparency.
The positive impact is already visible in export performance. Pakistan’s pharmaceutical exports recorded a remarkable 34 percent increase, representing the sector’s highest growth rate in nearly two decades. This reflects improved production capacity, stronger international market access, and growing confidence among industry participants.
Beyond economic gains, the reforms are delivering important public health benefits through better medicine availability, stronger regulatory oversight, and higher manufacturing standards. Increased domestic production capacity is also strengthening Pakistan’s resilience against future supply-chain disruptions and health emergencies.
Sustaining this momentum will require continued commitment to regulatory modernization, innovation, research, and reform implementation. Expanding export markets, strengthening local production of APIs and vaccines, and achieving full compliance with international standards remain critical priorities. With SIFC serving as a key facilitator, Pakistan’s pharmaceutical industry is steadily emerging as a dynamic, globally connected, and investment-ready sector capable of supporting both national healthcare needs and export-led economic development.
